168 related articles for article (PubMed ID: 11403179)
1. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
Waldherr C; Schumacher T; Pless M; Crazzolara A; Maecke HR; Nitzsche EU; Haldemann A; Mueller-Brand J
Nucl Med Commun; 2001 Jun; 22(6):673-8. PubMed ID: 11403179
[TBL] [Abstract][Full Text] [Related]
2. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
Waldherr C; Pless M; Maecke HR; Haldemann A; Mueller-Brand J
Ann Oncol; 2001 Jul; 12(7):941-5. PubMed ID: 11521799
[TBL] [Abstract][Full Text] [Related]
4. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
Merlo A; Hausmann O; Wasner M; Steiner P; Otte A; Jermann E; Freitag P; Reubi JC; Müller-Brand J; Gratzl O; Mäcke HR
Clin Cancer Res; 1999 May; 5(5):1025-33. PubMed ID: 10353735
[TBL] [Abstract][Full Text] [Related]
5. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.
Paganelli G; Zoboli S; Cremonesi M; Bodei L; Ferrari M; Grana C; Bartolomei M; Orsi F; De Cicco C; Mäcke HR; Chinol M; de Braud F
Eur J Nucl Med; 2001 Apr; 28(4):426-34. PubMed ID: 11357492
[TBL] [Abstract][Full Text] [Related]
6. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Paganelli G; Zoboli S; Cremonesi M; Mäcke HR; Chinol M
Cancer Biother Radiopharm; 1999 Dec; 14(6):477-83. PubMed ID: 10850334
[TBL] [Abstract][Full Text] [Related]
7. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
8. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
[TBL] [Abstract][Full Text] [Related]
9. Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
Waldherr C; Haldemann A; Maecke HR; Crazzolara A; Mueller-Brand J
Clin Oncol (R Coll Radiol); 2000; 12(2):121-3. PubMed ID: 10853753
[TBL] [Abstract][Full Text] [Related]
10. [Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma].
Gao ZR; An R; Zhang YX; Biersack HJ
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):621-4. PubMed ID: 17236560
[TBL] [Abstract][Full Text] [Related]
11. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
[TBL] [Abstract][Full Text] [Related]
12. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
[TBL] [Abstract][Full Text] [Related]
15. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Pless M; Waldherr C; Maecke H; Buitrago C; Herrmann R; Mueller-Brand J
Lung Cancer; 2004 Sep; 45(3):365-71. PubMed ID: 15301877
[TBL] [Abstract][Full Text] [Related]
16. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer.
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Roser HW; Bockisch A
Thyroid; 2001 Jul; 11(7):647-59. PubMed ID: 11484893
[TBL] [Abstract][Full Text] [Related]
17. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
[TBL] [Abstract][Full Text] [Related]
18. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
[TBL] [Abstract][Full Text] [Related]
20. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
